Proposal for classifying the acute emetogenicity of cancer chemotherapy. - Wikidata - wikimedia - TriplyDB

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

http://www.wikidata.org/entity/Q41314646

about

Cancer cachexia--pathophysiology and management An ETP model (exclusion-tolerance-progression) for multi drug resistance Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management Chemotherapy-induced nausea and vomiting: optimizing prevention and management Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.Advances in use of the 5-HT3 receptor antagonists.Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis.APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgro Gemcitabine and Vinorelbine (GemVin) Regimen Paclitaxel and trastuzumab for breast cancer.5-HT3 antiemetic therapy for patients with breast cancer.Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting.Antiemetics: American Society of Clinical Oncology clinical practice guideline update.Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron.Paclitaxel, Carboplatin, and trastuzumab.Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomiz Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Ital Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials.Symptom control.Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.An overview of the clinical use of ondansetron in preschool age children.Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries.Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting.

P2860

Q24605567-886A0F9E-1904-4B4D-9FC8-15DE1C8E1E06 Q24805788-264C6BBB-6404-413C-B34A-1FC245C3A436 Q26830695-B9114F88-D584-4A62-B451-41647BDEAA77 Q26852601-02F112E5-712A-4C19-8BCC-0D470FC270A1 Q30235971-B83E4719-1E1C-46B9-A4EF-7ACD61C00162 Q31045439-67889B12-B159-4F16-9C62-DDA3CC3114C2 Q33181781-B5EFC659-AFD6-4CEE-B18B-9AF78F0FAE61 Q33652946-C8826B04-A19F-4D54-B3D2-7CC4DB37161E Q33734386-4D4F73CA-0BA2-431C-803A-2AD155100815 Q33774738-5F9A8014-F6F5-4838-A046-130E054DD1F7 Q33774794-E806C0D9-48FF-4EDE-B8B7-4E38EEA76B59 Q33794552-909812AD-D07E-4EB2-ADA3-D219F7F20CBA Q33832042-C608B6B2-0BAA-4BE0-8A16-A01C98D1B2B3 Q33855964-31014D5B-3DF0-4BB7-863A-7C21CFED0E2B Q34030613-658C0FC3-10F9-4A8C-AAA3-9B39AABE0990 Q34418451-55790A06-6493-4C52-B642-5D7AD2DCA49E Q34612916-849F1418-E63F-406B-A648-36E0B193D492 Q34778628-2579AC49-9623-4E39-92E5-EDE50772907A Q34941162-3A7CDD03-85A3-4394-B187-0B9007D4ECD8 Q35028927-06467B5B-2974-4F45-9EA1-E1588ABEA106 Q35063100-41F77C92-F221-4778-A1B7-F920120805D2 Q35082647-249561D9-E0C6-41E0-9C66-F7944FC8D329 Q35146420-8EE4767E-398D-40D9-AC7B-3B1EF5DA3B23 Q35182204-3558836E-9F2F-4DB8-BBDA-751C92F2FFD7 Q35195218-E1DBB629-732B-4DB9-B16F-87D8530D25EF Q35195231-D82CDCC7-C347-4AF4-82DD-A4B1EB0B24E6 Q35201044-7960C89F-6AED-47F6-B2B4-2DFD7EB02A0C Q35208781-DAF5E99C-DCF5-4B73-A2ED-482758BFD615 Q35553856-72783B2D-A425-412C-9272-C051A866BC5E Q35571607-9DD2D7B2-FFBA-4DD9-9F6C-F2410ED28FF2 Q35918427-56573532-627B-4937-8F45-04E29ABD5F05 Q35919237-4A6D1CC2-3EC1-470E-9A67-A3FCFCF2C333 Q35938093-9F67F8E9-73EB-48C7-B761-D95584EE21AE Q35962019-EA40AD3D-0BD9-448A-BC0C-EF605DC4E569 Q35970506-66116347-5B62-4D78-94C0-A7A0ADB07CB0 Q35980236-F1FB7849-D0EB-475B-B9DF-0812B45EFFF4 Q36051908-7ECC5647-7D0F-4D09-B7A7-6241BDCB7816 Q36052217-4CF99FBE-10C2-46D3-B092-8397EA328A69 Q36064834-7D50AFE0-5A89-4517-8AF2-59E21998D741 Q36068646-987572F3-3C18-49C5-A753-5279AC7E4005

P2860

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

http://www.wikidata.org/entity/Q41314646

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

@en

type

label

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

@en

prefLabel

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

@en

P1433

Q41314646-3EBC9BA7-2F31-40BF-9F5E-0B995C1310E2

P1476

Q41314646-D6384DF9-2274-450B-9DF9-E4907F2B1994

P2093

Q41314646-04F2EF4A-3E7A-4393-8EF3-4089B82254B6

Q41314646-29352191-4F48-479F-B7F5-1AA7675E48A9

Q41314646-3A20D0A5-BF34-4E14-8546-F3F4A2D0695B

Q41314646-4C451622-9B91-4DE7-AB7C-ACB8D47A85E8

Q41314646-5185A094-2876-4D2C-A294-CB797313B414

Q41314646-5E3317D3-48F2-472A-B2CB-B2DD39A2B7B4

Q41314646-A6BCDA3B-D3BE-4FDC-ADA4-6F4413F5AA7C

Q41314646-D605490F-EA1D-4619-9B12-8E5104AE3C53

Q41314646-E3C3D5A6-BC75-45F3-96BD-2A8408D3AB64

P304

Q41314646-AE90B8B6-E314-4830-8EB7-24B732C5120E

P31

Q41314646-F094D2C7-8432-4BEC-BC59-1F30E433C0A0

P356

Q41314646-77F3C1DF-1C30-4C5A-B78A-708A77305272

P407

Q41314646-B102539E-1D09-4F48-B252-4E1026607463

P433

Q41314646-2049B4CB-E4C7-4E68-AB87-89B16F4472F1

P478

Q41314646-FC1242DF-51BD-41BC-B119-D8B869A71E63

P577

Q41314646-FA5BD556-4967-42F2-B25D-924695E41A4E

P698

Q41314646-867C4C17-BF52-43B9-8C13-BE1BF8C701A0

P921

Q41314646-231A85E3-36CB-4CD0-9990-598943F99B5B

P356

JCO.1997.15.1.103

P1433

Journal of Clinical Oncology

P1476

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

@en

P2093

C M Lindley

http://www.w3.org/2001/XMLSchema#string

D Gandara

http://www.w3.org/2001/XMLSchema#string

G Harker

http://www.w3.org/2001/XMLSchema#string

J D Hainsworth

http://www.w3.org/2001/XMLSchema#string

M G Kris

http://www.w3.org/2001/XMLSchema#string

M S Aapro

http://www.w3.org/2001/XMLSchema#string

P J Hesketh

http://www.w3.org/2001/XMLSchema#string

S M Grunberg

http://www.w3.org/2001/XMLSchema#string

T Beck

http://www.w3.org/2001/XMLSchema#string

P304

103-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.1997.15.1.103

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

1997-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8996130

http://www.w3.org/2001/XMLSchema#string

P921